Are They Stopping Compounded Semaglutide? Understanding the Future of GLP-1 Medications

Last reviewed: June 15, 2026

Last updated: June 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Nobody is switching compounded semaglutide off overnight, but the regulatory ground under it has already moved, and any source telling you the situation is unchanged is behind. The FDA's period of enforcement discretion regarding certain compounded GLP-1 preparations — the accommodation created while the approved products were in shortage — ended in 2025, on staged dates in February and March for tirzepatide and April and May for semaglutide. Compounding by a licensed pharmacy against a prescription for an individual patient remains a regulated activity. What changed is the shortage-era latitude, and with it the terms on which this category operates.

What Enforcement Discretion Actually Was

When an FDA-approved drug is in shortage, the agency has historically exercised discretion about certain compounding activity that would otherwise draw enforcement attention. That discretion is not a license, a grant of approval, or a permanent status. It is a temporary posture tied to a supply condition.

When the shortage resolved, the condition that supported the posture resolved with it. The staged end dates in 2025 were the formal expression of that. This is a normal regulatory sequence, but it was widely reported as if it were a ban, which it was not.

What Did Not Change

Traditional pharmacy compounding — a licensed pharmacy preparing a preparation for an individual patient pursuant to a valid prescription — remains lawful and regulated. The FDA publishes a standing explanation of what compounding is and where its limits lie.

What also did not change is regulatory category. Compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. That was true during the shortage and it is true now. A compounded preparation is not a generic; neither Ozempic nor Wegovy has an approved generic.

Why the Approved Supply Picture Looks Different Now

The approved product landscape has expanded considerably. The Wegovy label now covers injection across six strengths including a 7.2 mg Wegovy HD pen approved in March 2026, single-dose syringes, a single-patient-use FlexTouch pen delivering four 2.4 mg doses, and Wegovy tablets at 1.5, 4, 9 and 25 mg approved in December 2025.

The Ozempic label now lists single-dose prefilled syringes alongside its three multi-dose pen configurations. Oral semaglutide exists as Rybelsus and as Ozempic tablets. A much broader approved supply is a large part of why the shortage-era rationale no longer applies.

What the FDA Is Actively Policing

The agency's statement on unapproved GLP-1 drugs is specific. It has warned telehealth companies for marketing unapproved drugs including retatrutide, warned active pharmaceutical ingredient distributors, and established a green-list import alert covering GLP-1 APIs with potential quality concerns.

It has also flagged salt forms such as semaglutide sodium and semaglutide acetate as different active ingredients from the one used in approved drugs, stating it is not aware of any lawful basis for their use in compounding. And it has documented fraudulent compounded products whose labels name pharmacies that either do not exist or did not compound the product.

The Adverse Event Signal

As of May 31, 2026, the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes that state-licensed pharmacies that are not outsourcing facilities are not required to submit adverse events, so these are likely underreported.

It also identified dosing errors as a specific concern, including patients measuring and self-administering incorrect doses and clinicians miscalculating doses, and reports that may relate to prescribing beyond approved labeling — more product per dose, more frequent dosing, or faster escalation. That is a category-level quality signal worth weighing.

How to Read the Next Twelve Months

The direction of travel is toward tighter scrutiny of the compounded GLP-1 category and a continually expanding approved product set. Neither of those is a prediction that compounding disappears; both are reasons to prefer providers who describe the category accurately.

PlexusDx dispenses through licensed 503A compounding pharmacies following a clinical intake and a prescriber decision, and states the regulatory position plainly: compounded semaglutide is not an FDA-approved finished product, and it is not a generic version of any approved brand. A provider unwilling to say that is telling you something about how they will handle the next change.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Has the FDA banned compounded semaglutide?

No. Traditional compounding by a licensed pharmacy against a prescription for an individual patient remains a lawful, regulated activity. What ended in 2025 was the FDA's shortage-era enforcement discretion regarding certain compounded GLP-1 preparations, on staged dates in February and March for tirzepatide and April and May for semaglutide. That was a temporary posture tied to supply, not an approval.

Why did the enforcement discretion end?

Because the shortage that supported it resolved. Enforcement discretion in this context is a temporary regulatory posture tied to a supply condition, not a permanent status or a form of approval. The approved product landscape has also expanded substantially, with additional semaglutide presentations, higher-dose injection options and approved oral tablets now available.

Is compounded semaglutide FDA approved?

No. Compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed. This was true during the shortage period and remains true. A compounded preparation is also not a generic: neither Ozempic nor Wegovy has an FDA-approved generic version.

What safety concerns has the FDA raised about this category?

As of May 31, 2026 the agency reported 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, and noted these are likely underreported. It has also flagged dosing errors, use of salt forms such as semaglutide sodium and acetate as different active ingredients, improper shipping temperatures, and fraudulently labeled products.

What should I ask a compounding provider now?

Ask whether the pharmacy is state-licensed and verifiable, what form of the active ingredient is used and whether it is a salt form, how shipments are temperature-controlled, and whether a licensed clinician is available after the medication arrives. Also ask them to state plainly whether the product is FDA approved. A provider who describes a compounded drug as equivalent to an approved brand is misdescribing it.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.